Ms. Fink has advised numerous clients on their post-grant review and litigation strategies. In addition to these confidential matters, Ms. Fink routinely represents clients at the PTAB. Her recent representations include the following:
- Representation of a branded drug company in a litigation pending at the District of Delaware and related post-grant proceedings before the PTAB concerning the company’s multiple sclerosis drug.
- Representation of a generic drug company in a litigation before the District of New Jersey and related post-grant proceedings before the PTAB concerning the client’s proposed generic version of an anti-inflammatory eye-drop formulation. The dispute resulted in a successful settlement for the client.
- Representation of a pharmaceutical company in post-grant proceedings before the PTAB concerning a proposed biosimilar to an anti-rheumatic branded biologic product.